213 related articles for article (PubMed ID: 30719207)
1. Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies.
McEvoy AC; Pereira MR; Reid A; Pearce R; Cowell L; Al-Ogaili Z; Khattak MA; Millward M; Meniawy TM; Gray ES; Ziman M
Oncotarget; 2019 Jan; 10(2):113-122. PubMed ID: 30719207
[TBL] [Abstract][Full Text] [Related]
2. FOXL2 and TERT promoter mutation detection in circulating tumor DNA of adult granulosa cell tumors as biomarker for disease monitoring.
Groeneweg JW; Roze JF; Peters EDJ; Sereno F; Brink AGJ; Paijens ST; Nijman HW; van Meurs HS; van Lonkhuijzen LRCW; Piek JMJ; Lok CAR; Monroe GR; van Haaften GW; Zweemer RP
Gynecol Oncol; 2021 Aug; 162(2):413-420. PubMed ID: 34083028
[TBL] [Abstract][Full Text] [Related]
3. Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA.
Diefenbach RJ; Lee JH; Stewart A; Menzies AM; Carlino MS; Saw RPM; Stretch JR; Long GV; Scolyer RA; Rizos H
Front Oncol; 2022; 12():820510. PubMed ID: 35494035
[TBL] [Abstract][Full Text] [Related]
4. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
[TBL] [Abstract][Full Text] [Related]
5. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression.
Chang GA; Tadepalli JS; Shao Y; Zhang Y; Weiss S; Robinson E; Spittle C; Furtado M; Shelton DN; Karlin-Neumann G; Pavlick A; Osman I; Polsky D
Mol Oncol; 2016 Jan; 10(1):157-65. PubMed ID: 26440707
[TBL] [Abstract][Full Text] [Related]
6. Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma.
Váraljai R; Wistuba-Hamprecht K; Seremet T; Diaz JMS; Nsengimana J; Sucker A; Griewank K; Placke JM; Horn PA; von Neuhoff N; Shannan B; Chauvistré H; Vogel FCE; Horn S; Becker JC; Newton-Bishop J; Stang A; Neyns B; Weide B; Schadendorf D; Roesch A
JCO Precis Oncol; 2020; 3():. PubMed ID: 32914028
[TBL] [Abstract][Full Text] [Related]
7. Sensitive droplet digital PCR method for detection of
McEvoy AC; Calapre L; Pereira MR; Giardina T; Robinson C; Khattak MA; Meniawy TM; Pritchard AL; Hayward NK; Amanuel B; Millward M; Ziman M; Gray ES
Oncotarget; 2017 Oct; 8(45):78890-78900. PubMed ID: 29108273
[TBL] [Abstract][Full Text] [Related]
8. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
[TBL] [Abstract][Full Text] [Related]
9. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
[TBL] [Abstract][Full Text] [Related]
10. Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S; McNamara B; Mutlu L; Demirkiran C; Hartwich TMP; Harold J; Yang-Hartwich Y; Siegel ER; Santin AD
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240216
[TBL] [Abstract][Full Text] [Related]
11. Circulating Tumor DNA Harboring the
Sato A; Tanabe M; Tsuboi Y; Niwa T; Shinozaki-Ushiku A; Seto Y; Murakami Y
Thyroid; 2021 Dec; 31(12):1822-1828. PubMed ID: 34541884
[No Abstract] [Full Text] [Related]
12. From validity to clinical utility: the influence of circulating tumor DNA on melanoma patient management in a real-world setting.
Rowe SP; Luber B; Makell M; Brothers P; Santmyer J; Schollenberger MD; Quinn H; Edelstein DL; Jones FS; Bleich KB; Sharfman WH; Lipson EJ
Mol Oncol; 2018 Oct; 12(10):1661-1672. PubMed ID: 30113761
[TBL] [Abstract][Full Text] [Related]
13. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
[TBL] [Abstract][Full Text] [Related]
14. Detection of metastases using circulating tumour DNA in uveal melanoma.
Beasley AB; de Bruyn DP; Calapre L; Al-Ogaili Z; Isaacs TW; Bentel J; Reid AL; Dwarkasing RS; Pereira MR; Khattak MA; Meniawy TM; Millward M; Brosens E; de Klein A; Chen FK; Kiliҫ E; Gray ES
J Cancer Res Clin Oncol; 2023 Nov; 149(16):14953-14963. PubMed ID: 37608028
[TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analysis and Functional Imaging Provide Complementary Approaches for Comprehensive Disease Monitoring in Metastatic Melanoma.
Wong SQ; Raleigh JM; Callahan J; Vergara IA; Ftouni S; Hatzimihalis A; Colebatch AJ; Li J; Semple T; Doig K; Mintoff C; Sinha D; Yeh P; Silva MJ; Alsop K; Thorne H; Bowtell DD; Gyorki DE; Arnau GM; Cullinane C; Kee D; Brady B; Kelleher F; Dawson MA; Papenfuss AT; Shackleton M; Hicks RJ; McArthur GA; Sandhu S; Dawson SJ
JCO Precis Oncol; 2017 Nov; 1():1-14. PubMed ID: 35172485
[TBL] [Abstract][Full Text] [Related]
16. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma.
Braune J; Keller L; Schiller F; Graf E; Rafei-Shamsabadi D; Wehrle J; Follo M; Philipp U; Hussung S; Pfeifer D; Mix M; Duyster J; Fritsch R; von Bubnoff D; Meiss F; von Bubnoff N
JCO Precis Oncol; 2020 Nov; 4():20-31. PubMed ID: 35050727
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma.
Gray ES; Rizos H; Reid AL; Boyd SC; Pereira MR; Lo J; Tembe V; Freeman J; Lee JH; Scolyer RA; Siew K; Lomma C; Cooper A; Khattak MA; Meniawy TM; Long GV; Carlino MS; Millward M; Ziman M
Oncotarget; 2015 Dec; 6(39):42008-18. PubMed ID: 26524482
[TBL] [Abstract][Full Text] [Related]
19. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
[TBL] [Abstract][Full Text] [Related]
20. Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors - Results of a Prospective Biomarker Study.
Forschner A; Weißgraeber S; Hadaschik D; Schulze M; Kopp M; Kelkenberg S; Sinnberg T; Garbe C; Biskup S; Battke F
Onco Targets Ther; 2020; 13():5017-5032. PubMed ID: 32581559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
